Survival analyses using RFS from the date of chemotherapy. (A) Survival analyses show that low LINE-1 methylation status was closely associated with shorter RFS times (P = 0.040). (B) There was no significant difference in RFS according to the performance status (PS). (C) Survival analysis stratified by combinatory PS and LINE-1methyaltion statuses. The difference was significant between PS(0)/LINE-1(high) and PS(1)/LINE-1(low) (P = 0.021). (D) Survival analysis using the TNR value in higher BMI score patients. (TIF 3476 kb

Duo Chen (505788)

Gyeong Kang (3440075)

Nam Cho (3440081)

Sae-Won Han (177138)

Tae Lee (42532)

Tae-You Kim (73316)

Xianyu Wen (3440078)

Ye-Young Rhee (3440072)

Young Song (596308)

PubMed

This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.Abstract
              
                Background
                Low methylation status of LINE-1 in tumors is associated with poor survival in patients with colon cancer. Eastern Cooperative Oncology Group performance status (ECOG-PS) is a method to assess the functional status of a patient. We retrospectively evaluated the relationship between ECOG-PS and LINE-1 methylation in colorectal cancers (CRCs) and their prognostic impact in CRC or colon cancer patients receiving adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX).
              
              
                Results
                
                           LINE-1 methylation and microsatellite instability were analyzed in stage III or high-risk stage II CRCs (n = 336). LINE-1 methylation levels were correlated with clinicopathological features, including PS and recurrence-free survival (RFS). The association between the tumoral LINE-1 methylation level and PS was observed (OR = 2.56, P < 0.001). Differences in LINE-1 methylation levels in cancer tissue between the PS 0 and 1 groups were significant in patients older than 60years (P = 0.001), the overweight body mass index group (P = 0.005), and the stage III disease group (P = 0.008). Prognostic significances of LINE-1 methylation status or combined PS and LINE-1 methylation statuses were identified in stage III colon cancers, not in stage III and high-risk stage II CRCs. Low LINE-1 methylation status was closely associated with a shorter RFS time. The difference between PS(0)/LINE-1(high) and PS(≥1)/LINE-1(low) was significant, which suggests that colon cancer patients with concurrent PS(≥1)/LINE-1 (low) have a higher recurrence rate.
              
              
                Conclusions
                PS was associated with LINE-1 methylation in CRC tissue. LINE-1 methylation was associated with RFS in stage III colon cancer patients who were treated with adjuvant FOLFOX chemotherapy. Combined PS and LINE-1 methylation status might serve as a useful predictor of cancer recurrence

Chen, Duo

Wen, Xianyu

Song, Young Seok

Rhee, Ye-Young

Lee, Tae Hun

Cho, Nam Yun

Han, Sae-Won

Kim, Tae-You

Kang, Gyeong Hoon

SNU Open Repository and Archive

Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients

Background: Low methylation status of LINE-1 in tumors is associated with poor survival in patients with colon cancer. Eastern Cooperative Oncology Group performance status (ECOG-PS) is a method to assess the functional status of a patient. We retrospectively evaluated the relationship between ECOG-PS and LINE-1 methylation in colorectal cancers (CRCs) and their prognostic impact in CRC or colon cancer patients receiving adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX).   Results: LINE-1 methylation and microsatellite instability were analyzed in stage III or high-risk stage II CRCs (n = 336). LINE-1 methylation levels were correlated with clinicopathological features, including PS and recurrence-free survival (RFS). The association between the tumoral LINE-1 methylation level and PS was observed (OR = 2.56, P &lt; 0.001). Differences in LINE-1 methylation levels in cancer tissue between the PS 0 and 1 groups were significant in patients older than 60 years (P = 0.001), the overweight body mass index group (P = 0.005), and the stage III disease group (P = 0.008). Prognostic significances of LINE-1 methylation status or combined PS and LINE-1 methylation statuses were identified in stage III colon cancers, not in stage III and high-risk stage II CRCs. Low LINE-1 methylation status was closely associated with a shorter RFS time. The difference between PS(0)/LINE-1(high) and PS(&gt;= 1)/LINE-1(low) was significant, which suggests that colon cancer patients with concurrent PS(&gt;= 1)/LINE-1 (low) have a higher recurrence rate.   Conclusions: PS was associated with LINE-1 methylation in CRC tissue. LINE-1 methylation was associated with RFS in stage III colon cancer patients who were treated with adjuvant FOLFOX chemotherapy. Combined PS and LINE-1 methylation status might serve as a useful predictor of cancer recurrence.Basic Science Research Program through the National Research Foundation   of Korea (NRF) - Ministry of Education [2013R1A1A2059080]; Priority   Research Centers Program through the National Research Foundation of   Korea (NRF) - MEST [2009-0093820]; NRF grant - Ministry of Science, ICT,   and Future Planning (MSIP) [2011-0030049]; Korean Health Technology R&amp;D   Project through the Korea Health Industry Development Institute (KHIDI)   - Ministry of Health &amp; Welfare, Republic of Korea [HI14C1277]SCI(E)PubMedARTICLEghkang@snu.ac.kr36

Institutional Repository of Peking University

Clinical Epigenetics

Associations and prognostic implications of Eastern Cooperative Oncology   Group performance status and tumoral LINE-1 methylation status in stage   III colon cancer patients

Duo Chen

Xianyu Wen

Young Seok Song

Ye-Young Rhee

Tae Hun Lee

Nam Yun Cho

Sae-Won Han

Tae-You Kim

Gyeong Hoon Kang

Springer - Publisher Connector

FigShare